Statement by Ralph G. Neas, President and CEO, GPhA, Regarding IMS Findings on the Use of Medicines in 2013

Published Online: Wednesday, April 16, 2014
Follow Pharmacy_Times:

WASHINGTON, DC, (April 16, 2014) – “The Generic Pharmaceutical Association (GPhA) welcomes this year’s IMS Institute for Healthcare Informatics report showing the critical role of generic medicines in saving billions of dollars for the health system and the economy. The study finds that even as utilization of medical services increased, the cost of medicines went up by just 3.2%, a historically low rate.

The low rate of spending on medicines in 2013 is a testament to the ongoing impact of generic drugs. This study reinforces that by relying on generic medicines, we can help ensure that as more Americans access medical services, the costs of medicines can be kept in check. This principle is critical for the coming year, as the number of insured Americans increases as a result of the Affordable Care Act.

The report, Medicine Use and Shifting Costs of Healthcare: A Review of the Use of Medicines in the United States in 2013, also finds that generic drugs are passing on savings to retail consumers. It notes that almost entirely due to generic drugs, 57% of medications are available to patients at a cost of five dollars or less.

Indeed, an IMS health analysis released by GPhA in December 2013 showed that generic pharmaceuticals have achieved $1.2 trillion in savings over the past decade, nearly $217 billion in 2012 alone, all of which translates to more than one billion dollars in savings every other day.

This report demonstrates the positive effect that generic medicines have had to date, but we can do even more. GPhA continues to call on Congress to enact common-sense reforms to save billions more for American taxpayers. This includes passing legislation to curb the abuse of the FDA’s Risk Evaluation and Mitigation Strategies (REMS) programs, which are being used to hinder competition, and measures to increase generic drug use for the Medicare Low Income Subsidy (LIS) population. According to CBO, this could result in more than $20 billion in savings to the federal government.”
Related Articles
The Generic Pharmaceutical Association has serious concerns about the unbalanced structure of the Trans-Pacific Partnership agreement in its current form.
GPhA has agreed to support compromise automatic substitution legislation that would allow interchangeable biologics to be automatically substituted at the pharmacy. This step brings millions of Americans closer to the day when they will be able to access safe alternatives to costly biologic medicines. Indeed, Express Scripts projects savings of $250 billion in 10 years should only the 11 likeliest biosimilars enter the market.
“GPhA applauds FDA for taking helpful steps to address, and hopefully limit, scenarios in which some brand drug companies misuse Risk Evaluation and Mitigation Strategies programs to thwart competition from more affordable generic drugs. The ongoing abuse of REMS and REMS-like programs costs the American health system and its patients $5.4 billion annually, according to a study conducted by Matrix Global Advisors. Interestingly, as the United States market readies for biosimilars, this same study identifies $140 million in lost savings that would occur for every $1 billion in biologics sales.
The Generic Pharmaceutical Association announced that it has named Terry Bazyluk as Vice President for Communications, effective December 1, 2014.
Latest Issues